About Antibody Drug Conjugates

Combining the selectivity of monoclonal antibodies with potent cytotoxic agents

Antibody drug conjugate (ADC) technology leverages the selectivity of monoclonal antibodies (MAbs) to offer novel possibilities to cancer patients.¹ This approach has been utilized in the management of select hematologic malignancies and solid tumors.^1,2

ADCs can be an effective and targeted vehicle designed to deliver potent cytotoxic agents directly to tumor cells through selective antibody binding.³

ADCs are a rational vehicle to exploit the internalization of monoclonal antibodies for the delivery of a potent cytotoxic agent inside target cells.^3,4

This technology may be applied as foundational ADC therapy or as a potential complement to existing treatment approaches.¹

Genentech is currently investigating the potential of using an ADC with other agents such as traditional monoclonal antibodies, including PD-L1 inhibitors, small molecules, and T-cell bispecific antibodies.^5,6